INBP — Integrated Biopharma Income Statement
0.000.00%
Last trade - 00:00- $8.79m
- $6.33m
- $50.32m
- 100
- 99
- 52
- 97
Annual income statement for Integrated Biopharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 52.8 | 63.6 | 56.2 | 50.7 | 50.3 |
| Cost of Revenue | |||||
| Gross Profit | 6.73 | 9.48 | 6.55 | 4.06 | 3.88 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 49.5 | 56.1 | 53.5 | 50.6 | 50.1 |
| Operating Profit | 3.26 | 7.44 | 2.75 | 0.12 | 0.251 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 3.09 | 7.25 | 2.6 | 0.1 | 0.268 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 4.11 | 8.01 | 3.84 | -0.016 | 0.113 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 4.11 | 8.01 | 3.84 | -0.034 | 0.112 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 4.11 | 8.01 | 3.88 | -0.034 | 0.112 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.132 | 0.216 | 0.12 | -0.001 | 0.004 |